Hippocampal Hypometabolism Predicts Cognitive Decline From Normal Aging
Deerfield, ILLINOIS - - March 31, 2008 - - Researchers at New York University have published results
of a study showing their ability to make highly accurate differential diagnoses of dementia using
The results, published in the Journal of Nuclear Medicine, demonstrated that the ability to combine
measurements of glucose metabolism in a region called the hippocampus with measurements in
other brain regions significantly increases the accuracy of differential diagnosis. Diagnostic
specificity in distinguishing between Alzheimer's Disease and another form of dementia, Lewy Body
Dementia, increased from 71% to 100% with the New York University approach, for an overall
accuracy of 99%. Specificity of differentiating between Alzheimer's Disease and a third form of
dementia, Frontotemporal Dementia, increased from 65% to 94%, for an overall accuracy of 97%.
Accuracy in distinguishing Alzheimer's Disease from Normals was 98%. The New York University
method was also able to distinguish Mild Cognitive Impairment (an earlier stage of decline that may
or may not lead to Alzheimer's Disease) from Normal individuals with a 95% accuracy, and was able
to identify disease-characteristic patterns within those patients.
The hippocampus is centrally involved in the encoding of new memories, and has been identified as
one of the first regions affected by Alzheimer's Disease and certain other dementias. Dr. Lisa
Mosconi and colleagues at New York University have developed a unique method allowing
automated measurement of hippocampal glucose metabolism from Positron Emission Tomography
(PET) images, which they applied to scans of 548 individuals between the ages of 50 and 85,
imaged at seven locations in the United States and Europe.
The ability to predict cognitive decline is becoming increasingly important given an aging population,
the increasing prevalence of neurological disorders as people live longer, and the number of
promising drugs in development for treatment of dementia. Even with the drugs available today, the
opportunity for patient benefit increases when the disease is identified early in progression.
Alzheimer's Disease affects an estimated 5 million people today in the United States alone, with
another 12 million or more people in pre-symptomatic or Mild Cognitive Impairment phases of
Abiant announced previously that it has secured an exclusive worldwide license to the technology
developed at New York University that allowed the detection of these changes in the hippocampus.
Abiant, Inc. uses proprietary image analysis methods and software to provide a sensitive biomarker
of drug effects and disease progression. The imaging information, which includes biochemical,
functional, and structural measurements, can be used to accelerate or reduce risk of decision
making in both drug development and disease treatment. The Company’s focus areas include the
central nervous system, oncology, and inflammation. Further information can be found at www.
Forward Looking Statements
This press release may contain "forward-looking" statements identified by words such as “will,”
"achieve," and "enable." There are a number of important factors that could cause Abiant's results to
differ materially from those indicated by these forward-looking statements.
|Copyright 2006-2010 Abiant, Inc.
|Abiant, Inc. 480 West Center Street, Suite 202, Grayslake, Illinois 60030